The strong beat on 2025 guidance and robust 2026 outlook suggest accelerating growth in Privia's value-based care model. Traders should monitor the company's ability to maintain high growth rates in attributed lives and provider count while expanding margins. The 80% free cash flow conversion target in 2026 could support potential share buybacks or strategic acquisitions.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $24.91entry
- T+1 · 9mo ago −4.66%α −4.20% · $23.75
- T+5 · 9mo ago −4.30%α −3.17% · $23.84
- T+20 · 8mo ago −18.99%α −12.59% · $20.18
- T+60 · 6mo ago −9.11%α −16.86% · $22.64
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Privia Health reported strong full-year 2025 results with revenue of $2.12 billion (up 22.3% YoY), net income of $22.9 million (up 59.3%), and Adjusted EBITDA of $125.5 million (up 38.8%). All key metrics exceeded guidance. For 2026, the company guided for revenue of $2.35-$2.45 billion and Adjusted EBITDA of $145-$155 million, reflecting continued growth and strong cash flow generation with no debt.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $2.12 billion, up 22.3% YoY from $1.74 billion in 2024
- Full-year 2025 net income was $22.9 million, up 59.3% YoY from $14.4 million in 2024
- Full-year 2025 Adjusted EBITDA was $125.5 million, up 38.8% YoY from $90.5 million in 2024
- All 2025 operating and financial metrics were at or above the high end of guidance
- 2026 guidance: revenue of $2.35-$2.45 billion (10.7%-15.4% growth), Adjusted EBITDA of $145-$155 million (15.5%-23.5% growth)
- Company ended 2025 with $479.7 million in cash and no debt
Financial Impact
Revenue increased by $386.4 million, net income by $8.5 million, and Adjusted EBITDA by $35 million year-over-year
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Implemented Providers | $5.4K | +12.3% |
| Attributed Lives | $1.5M | +22.7% |
Risk Factors
- Forward-looking guidance is not reconciled to GAAP measures, creating uncertainty around profitability
- Heavy reliance on value-based risk arrangements in the challenging Medicare Advantage market
- Potential for decreased reimbursement rates from government and private payers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759655-26-000007 |
| Document: prva-20260226.htm | 0001759655-26-000007 |
| Document: 0001759655-26-000007-index-headers.html | 0001759655-26-000007 |
| Document: 0001759655-26-000007-index.html | 0001759655-26-000007 |
| Document: 0001759655-26-000007.txt | 0001759655-26-000007 |
| CONTEXT: Previous Earnings (2026-02-26) | 0001759655-26-000007 |
Track record
20 reports on PRVA
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.73% at T+60 after the Mar 9, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Mixed 6/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $23.94 to $23.67 Now $25.26 −5.51% ▲ +1.13% +4.42% vs SPY
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $21.28 to $24.54 Now $25.26 +18.70% ▲ +15.32% +15.24% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $21.48 to $24.42 Now $25.26 +17.60% ▲ +13.69% +16.39% vs SPY
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $20.30 to $21.67 Now $25.26 +24.43% ▲ +6.75% +7.73% vs SPY
- Jul 13, 202618w ago Insider Cluster Neutral 3/10 Entry $28.03 to $26.26 Now $25.26 −9.88% ▼ −6.31% −5.02% vs SPY
- Jul 9, 202618w ago Insider Cluster Neutral 3/10 Entry $27.49 to $26.90 Now $25.26 −8.11% ▼ −2.15% −0.60% vs SPY
- Jul 7, 202618w ago Insider Cluster Neutral 3/10 Entry $27.21 to $28.10 Now $25.26 −7.17% ▲ +3.27% +2.01% vs SPY
- Jul 7, 202618w ago Press Release Neutral 1/10 Entry $27.23 to $28.03 Now $25.26 −7.23% ▲ +2.94% +2.39% vs SPY
- Jul 2, 202619w ago Insider Cluster Neutral 3/10 Entry $27.36 to $27.77 Now $25.26 −7.68% ▲ +1.50% +0.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers